ScreenerHero

PROK ProKidney Corp.

NAS · US · Healthcare · Biotechnology · prokidney.com
1.570USD-1.88%Mkt Cap: 626.72M $P/E: —

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy wi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap626.72M USD
Enterprise Value1.26B USD
Revenue (TTM)818.00K USD
Gross Profit818.00K USD
Net Income (TTM)-68.99M USD
Revenue/Share0.0050 USD
Last Price1.570 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees231
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.73
PEG—
EV/EBITDA-7.41
EV/Revenue1543.54
P/S780.80
P/B-0.37
EPS (TTM)-0.55
EPS (Forward)-0.59
52W Range
1.30012% of range3.480
52W High3.480 USD
52W Low1.300 USD
Profitability
Gross Margin100.00%
Oper. Margin-32248.67%
EBITDA Margin0.00%
Profit Margin-7725.20%
ROE6.82%
ROA-20.56%
Growth
Revenue Growth-32.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-120.12M USD
CapEx (TTM)15.20M USD
FCF Margin-10249.98%
FCF Yield-13.38%
Net Debt-178.04M USD
Net Debt/EBITDA1.05
Balance Sheet
Debt/Equity-0.00
Current Ratio8.36
Quick Ratio8.04
Book Value/Sh-4.29 USD
Cash/Share0.87 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)6.250 USD
Upside (mean)+298.1%
Target Range1.000 USD – 12.00 USD
1.000+298.1% to mean12.00
# Analysts6
Ownership
Shares Out.208.93M
Float184.65M
Insiders46.45%
Institutions26.53%
Short Interest
Short Ratio18.5d
Short % Float13.80%
Short % Out.10.26%
Shares Short21.45M
Short (prev mo.)21.49M
Technical
SMA 501.681 (-6.6%)
SMA 2001.899 (-17.3%)
Beta1.80
S&P 52W Chg16.45%
Avg Vol (30d)1.48M
Avg Vol (10d)1.35M
Technical Indicators
RSI (14)42.1
MACD-0.0295
MACD Signal-0.0072
MACD Hist.-0.0223
BB Upper2.009 USD
BB Middle1.740 USD
BB Lower1.470 USD
BB Width30.99%
ATR (14)0.1074 USD
Vol Ratio (20d)0.49x